Group 1 - The core viewpoint of the news is that Zhijiang Biotech's stock has shown a slight increase of 1.07%, reaching a price of 19.87 CNY per share, with a total market capitalization of 3.818 billion CNY [1] - Zhijiang Biotech, established on April 18, 2005, specializes in the research, production, and sales of molecular diagnostic reagents and equipment, with a significant revenue contribution from nucleic acid testing kits at 86.47% [1] - The company's revenue breakdown indicates that other products account for 11.99%, while molecular diagnostic instruments contribute 1.54% [1] Group 2 - Among the top circulating shareholders of Zhijiang Biotech, Dazhong Fund's Dazhong Jingheng Mixed A (090019) holds 909,200 shares, representing 0.47% of the circulating shares, with no change in the number of shares held compared to the previous period [2] - Dazhong Jingheng Mixed A has achieved a year-to-date return of 41.96% and a one-year return of 37.38%, ranking 1840 out of 8087 and 2005 out of 8085 in its category, respectively [2] - The fund manager, Su Bingyi, has a tenure of 13 years and 329 days, with the fund's total asset size at 1.9 billion CNY and a best return of 250.69% during his management period [2]

Group 1 - The core point of the news is that Zhijiang Bio has seen a 5% increase in stock price, reaching 23.94 CNY per share, with a total market capitalization of 4.6 billion CNY [1] - Zhijiang Bio, established on April 18, 2005, specializes in the research, production, and sales of molecular diagnostic reagents and equipment, with 86.47% of its revenue coming from nucleic acid testing kits [1] - The company is located in Minhang District, Shanghai, and was listed on January 18, 2021 [1] Group 2 - Among the top circulating shareholders of Zhijiang Bio, Dazhong Fund's Dazhong Jingheng Mixed A (090019) holds 909,200 shares, unchanged from the previous period, representing 0.47% of circulating shares [2] - Dazhong Jingheng Mixed A has achieved a year-to-date return of 46.93%, ranking 1332 out of 8140 in its category [2] - The fund was established on June 15, 2012, and has a current scale of 694 million CNY, with a cumulative return of 393.36% since inception [2]

Core Viewpoint - Zhijiang Biotech experienced a decline of 5.03% on September 23, with a stock price of 22.86 CNY per share and a total market capitalization of 4.393 billion CNY [1] Company Overview - Zhijiang Biotech, established on April 18, 2005, and listed on January 18, 2021, is located in Minhang District, Shanghai. The company specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of the company includes 86.47% from nucleic acid testing kits, 11.99% from other products, and 1.54% from molecular diagnostic instruments [1] Shareholder Information - Among the top ten circulating shareholders of Zhijiang Biotech, a fund under Rongtong Fund holds 1.5 million shares, unchanged from the previous period, representing 0.78% of the circulating shares. The estimated floating loss today is approximately 1.815 million CNY [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) was established on December 25, 2014, with a current scale of 2.074 billion CNY. Year-to-date returns are 19.74%, ranking 4408 out of 8172 in its category, while the one-year return is 46.63%, ranking 3544 out of 7995 [2] Fund Manager Information - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has been in the position for 9 years and 31 days. The total asset scale of the fund is 5.629 billion CNY, with the best return during his tenure being 155.09% and the worst being -17.06% [3]

广发价值核心混合A（010377）成立日期2021年1月22日，最新规模35.16亿。今年以来收益68.54%，同 类排名147/8194；近一年收益114.67%，同类排名129/7963；成立以来亏损0.78%。 广发价值核心混合A（010377）基金经理为吴远怡。 截至发稿，吴远怡累计任职时间4年333天，现任基金资产总规模204.78亿元，任职期间最佳基金回报 113.46%， 任职期间最差基金回报-17.06%。 8月27日，之江生物跌5.13%，截至发稿，报25.71元/股，成交2.01亿元，换手率3.94%，总市值49.40亿 元。 资料显示，上海之江生物科技股份有限公司位于上海市闵行区陈行公路2168号9号楼，成立日期2005年4 月18日，上市日期2021年1月18日，公司主营业务涉及分子诊断试剂及仪器设备的研发、生产和销售。 主营业务收入构成为：核酸检测试剂盒82.71%，其它10.54%，分子诊断仪器5.00%，其他(补充)1.75%。 从之江生物十大流通股东角度 数据显示，广发基金旗下1只基金位居之江生物十大流通股东。广发价值核心混合A（010377）一季度 持有股数481.72万股， ...

Core Viewpoint - Zhijiang Biotechnology experienced a 5% decline in stock price, currently trading at 27.53 CNY per share, with a market capitalization of 5.29 billion CNY [1] Company Overview - Shanghai Zhijiang Biotechnology Co., Ltd. was established on April 18, 2005, and went public on January 18, 2021. The company specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of the company includes: 82.71% from nucleic acid testing kits, 10.54% from other products, 5.00% from molecular diagnostic instruments, and 1.75% from other sources [1] Shareholder Information - Dazhong Fund's Dazhong Jingheng Mixed A (090019) is among the top ten circulating shareholders of Zhijiang Biotechnology, holding 909,200 shares, which represents 0.47% of the circulating shares. The fund has incurred an estimated floating loss of approximately 1.32 million CNY today [2] - Dazhong Jingheng Mixed A was established on June 15, 2012, with a current scale of 397 million CNY. Year-to-date returns are 37.41%, ranking 1284 out of 8194 in its category, while the one-year return is 103.51%, ranking 262 out of 7962. Since inception, the fund has achieved a return of 361.38% [2] Fund Management - The fund manager of Dazhong Jingheng Mixed A is Su Bingyi, who has a tenure of 13 years and 203 days. The total asset size of the fund is 1.24 billion CNY, with the best return during his tenure being 240.01% and the worst being -71.74% [3] Fund Holdings - Dazhong Jingheng Mixed A holds 909,200 shares of Zhijiang Biotechnology, unchanged from the previous period, accounting for 1.97% of the fund's net value, making it the sixth-largest holding. The estimated floating loss today is approximately 1.32 million CNY [4]

Group 1 - The core point of the news is that Zhijiang Bio experienced a 5% drop in stock price, currently trading at 27.53 yuan per share, with a total market capitalization of 5.29 billion yuan [1] - Zhijiang Bio, established on April 18, 2005, and listed on January 18, 2021, specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of Zhijiang Bio includes 82.71% from nucleic acid testing kits, 10.54% from other products, 5.00% from molecular diagnostic instruments, and 1.75% from other sources [1] Group 2 - Among the top circulating shareholders of Zhijiang Bio, a fund under Rongtong Fund has reduced its holdings by 200,000 shares, now holding 1.5 million shares, which represents 0.78% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 2.074 billion yuan and has achieved a year-to-date return of 24.46%, ranking 3000 out of 8194 in its category [2] - The fund has a one-year return of 48.49%, ranking 2565 out of 7962, and a cumulative return since inception of 200.7% [2] Group 3 - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has been in the position for 9 years and 3 days [3] - The total asset scale of the fund is 4.223 billion yuan, with the best return during Wan's tenure being 163.77% and the worst being -14.89% [3]